Fidelity Investments’s Protalix BioTherapeutics PLX Stock Holding History

Fidelity Investments’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.96K	Buy	2,989 +84	+3%	+$178	﹤0.01%	4954
2026 Q1	$6.3K	Buy	2,905 +590	+25%	+$1.46K	﹤0.01%	4868
2025 Q4	$4.17K	Buy	2,315 +1,877	+429%	+$3.84K	﹤0.01%	4922
2025 Q3	$972	Buy	+438	New	+$713	﹤0.01%	5021
2024 Q3	–	Sell	-6,791	Closed	-$7.95K	–	5681
2024 Q2	$7.95K	Buy	6,791 +4,265	+169%	+$5.04K	﹤0.01%	4412
2024 Q1	$3.18K	Buy	2,526 +2,456	+3,509%	+$3.67K	﹤0.01%	4611
2023 Q4	$125	Sell	70 -279	-80%	-$434	﹤0.01%	4923
2023 Q3	$580	Buy	349 +244	+232%	+$438	﹤0.01%	4700
2023 Q2	$210	Buy	+105	New	+$250	﹤0.01%	4899
2020 Q3	–	Sell	-2	Closed	–	–	3924
2020 Q2	$0	Hold	2	–	–	﹤0.01%	4040
2020 Q1	$0	Hold	2	–	–	﹤0.01%	4121
2019 Q4	$0	Buy	+2	New	+$5	﹤0.01%	4160
2014 Q3	–	Sell	-106,679	Closed	-$3.89M	–	2815
2014 Q2	$3.89M	Sell	106,679 -8,000	-7%	-$323K	﹤0.01%	2293
2014 Q1	$5.25M	Hold	114,679	–	–	﹤0.01%	2195
2013 Q4	$4.46M	Hold	114,679	–	–	﹤0.01%	2202
2013 Q3	$5.2M	Sell	114,679 -5,230	-4%	-$268K	﹤0.01%	2143
2013 Q2	$5.89M	Buy	+119,909	New	+$6.36M	﹤0.01%	2091

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Fidelity Investments's PLX Position: Q2 2026 in Review

Fidelity Investments increased its Protalix BioTherapeutics (PLX) stake by 2.9% in Q2 2026, buying an estimated $178 and bringing the position to 2,989 shares worth $6.96K. The position accounts for ﹤0.01% of the portfolio, ranked #4954.

Fidelity Investments first reported a position in PLX in Q2 2013 and has held it in 17 quarters since. The position peaked at $5.89M in Q2 2013. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Fidelity Investments held 2,989 shares of Protalix BioTherapeutics worth $6.96K as of Q2 2026.
Fidelity Investments bought 84 Protalix BioTherapeutics shares in Q2 2026, an estimated $178.
Protalix BioTherapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4954 holding.
Fidelity Investments first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 17 quarters since.
Fidelity Investments's Protalix BioTherapeutics position peaked at $5.89M in Q2 2013.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.